公开(公告)号：EP3331915A1

公开(公告)日：2018-06-13

申请号：EP16757165.2

申请日：2016-08-05

申请人： Amgen Research (Munich) GmbH

发明人： FIEDLER, Walter ,  WELLBROCK, Jasmin ,  STAMM, Hauke ,  KLINGLER, Felix

IPC分类号： C07K16/28 ,  G01N33/574 ,  A61K39/395 ,  A61P35/02

CPC分类号： C07K16/2851 ,  A61K39/0011 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/74 ,  Y02A50/466

摘要： The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.